

Endothelial Progenitor Cells and Exercise-Induced Redox Regulation

Sven Moebius-Winkler, Gerhard Schuler, and Volker Adams

Abstract

Endothelial progenitor cells (EPCs) are thought to participate in endothelial cell regeneration and neovascularization in either a direct or an indirect way. The number of circulating EPCs is influenced by many factors like disease status, medication, age, and fitness level and is an independent predictor of disease progression and cardiovascular events. Experimental as well as clinical studies during the last 10 years clearly demonstrated that physical exercise training has a beneficial effect on endothelial function, which is a clear predictive value for cardiovascular mortality. Over the last years mainly clinical studies provided solid evidence for an exercise training induced mobilization of EPCs from the bone marrow, thereby possibly influencing the regeneration of the endothelial cell layer. This review will discuss the mechanisms how exercise induces mobilization of EPCs from the bone marrow with a focus on the influence on the redox balance. *Antioxid. Redox Signal.* 15, 997–1011.

Introduction

SINCE THE FIRST description of endothelial progenitor cells (EPCs) by Asahara and coworkers in 1997 (9), a huge amount of literature has been published on EPCs in cardiovascular (CV) diseases. Adult bone marrow (BM) (9) as well as other organs (6) are reservoirs of tissue-specific stem and progenitor cells. Among these, a scarce population of cells described as EPCs can be mobilized by various stimuli, including exercise training into the circulation to contribute to the neoangiogenic process or the repair of a damaged endothelial cell layer. Circulating levels of EPCs independently predict CV disease progression and exhibit a negative correlation with the Framingham risk factor score, CV events, and endothelial function (38, 93, 121). There has been no systematic study of the number of EPCs present in healthy individuals. However, several investigations have been reported showing that the number and function of EPCs decline with age (39), physical inactivity (107), and the occurrence of several diseases like diabetes (106) and chronic kidney disease (55). Before we go into the discussion of how exercise training by regulating the redox balance leads to a mobilization of EPCs, we would like to give a short introduction into the cell type EPCs and how we can detect this specific cell type with high accuracy.

EPCs: Definition and Detection

Even 13 years after the first description of EPCs (9) we have not a clear and definitive marker set to characterize and to quantify circulating EPCs with high accuracy. There is an on-

going debate whether these cells represent a structurally and functionally homogeneous population (43). Although the BM has been shown to be a principal source of EPC, it is probably not the only one, as stem/progenitor cells with endothelial cell-like properties have been isolated from different tissues, including peripheral blood, adipose, and cardiac muscle tissue (112). So, we are still trying to answer the question about the phenotype of a true EPC. This point makes it really difficult to standardize and compare the quantification of EPCs among different published studies. Another critical point in the definition of the cells involved in repairing damaged endothelium is the nomenclature for the cells used in different studies. A summary of the different names is given in Table 1. Some names are based purely on cell surface markers, whereas other names deviated from properties observed in cell culture.

Nevertheless, the most often used techniques for evaluating EPCs are flow cytometry and the quantification of colony forming units after cell culture.

Flow cytometry

The beauty of this methodology is that it can characterize cells at the single-cell level with the use of antibodies directed against specific cell surface markers and that a quantitative analysis of cells in solution can be rapidly achieved. In most cases a combination of a hematopoietic stem cell marker, like CD34, CD117 (cKit), or CD133, with a marker for endothelial cells, like vascular endothelial growth factor (VEGF) receptor 2 (KDR) or Ve-cadherin, is used to identify EPCs [summarized in (1, 40, 111)]. In general, the best approach to characterize and

TABLE 1. SUBTYPES OF PUTATIVE ENDOTHELIAL PROGENITOR CELLS, AND ANGIOGENIC AND VASCULOGENIC CELLS

Acronym	Meaning	Comment
EPC (9)	Endothelial progenitor cells	Population of rare cells that circulate in the blood with the ability to differentiate into endothelial cells. A pool of mixed cells.
CFU-ECs (123)	Colony-forming unit endothelial cells	CFU-ECs, derived from the hematopoietic system, with no ability to form secondary endothelial colonies <i>in vitro</i> or new vessels <i>in vivo</i> .
CACs (85)	Circulating angiogenic cells	In distinction from circulating EPCs culturing of mononuclear cells (MNCs) on fibronectin yields CACs. This cell population has been recently redefined to distinguish the cells from EPCs, as the latter do not appear to express monocyte/macrophage markers.
CEPs (25)	Circulating endothelial precursors	Has to be regarded as the equivalent to EPCs, based on cell surface marker expression.
ECFC (44)	Endothelial colony-forming cells	ECFCs belong to the endothelial lineage, which are also referred to as blood outgrowth endothelial cells (BOECs) (62).
LPP-ECFC (44)	Low proliferative potential ECFC	A unique population of LPP-ECFC in human cord blood that can achieve 20–30 population doublings, but they do not form secondary colonies on replating.
HPP-ECFC (44)	High proliferative potential ECFC	A unique population of HPP-ECFC in human cord blood that can achieve at least 100 population doublings, replating into at least secondary and tertiary colonies, and retain high levels of telomerase activity.
Early outgrowth EPC (38)	Early outgrowth endothelial progenitor cells	Plating of MNCs into endothelial-specific medium, and these cells arise after 5–7 days in culture.
Late outgrowth EPC (38)	Late outgrowth endothelial progenitor cells	Plating of MNCs into endothelial-specific medium, and these cells arise after 14 days in culture.

quantify EPCs would be to include as many markers as possible. Nevertheless, this is limited by the low abundance of EPCs in the peripheral blood, which represent between 0.01% and 0.0001% of mononuclear cells depending on several factors like age, state of health of the individual, as well as medication.

Another factor complicating the characterization of EPCs is that the expression of the often used stem cell marker CD34 is not only restricted to stem cells, but is also expressed on mature microvascular endothelial cells (21, 91). Therefore, CD133, a more immature hematopoietic stem cell marker that is absent on mature endothelial cells and monocytic cells (32), was introduced as a better marker for EPCs. It is postulated that CD133^{pos}/KDR^{pos} cells more likely reflect immature progenitor cells, whereas CD34^{pos}/KDR^{pos} may also represent shed cells of the vessel wall. In addition, it is suggested by several authors that more immature EPCs in the BM are CD133^{pos}/CD34^{pos}/KDR^{pos}/Ve-cadherin^{neg}, whereas circulating EPCs lose the early marker CD133 and start to express more endothelial cell marker [review in (40)]. Therefore, they are defined as CD133^{neg}/CD34^{pos}/KDR^{pos}/Ve-cadherin^{pos}. In conclusion, the proper identification of EPCs by flow cytometry is still uncertain, but for practical reasons the definition CD34^{pos}/KDR^{pos} is most often used.

Cell culture

Classical isolation methods include adherence culture of total peripheral mononuclear cells (9) and the use of magnetic beads coated with anti-CD34 (9), anti-CD133 (82), or anti-

CD14 (96, 113, 124) antibodies. After the isolation, the cells are plated on cell culture dishes coated either with fibronectin (17, 106, 116), collagen I (62), or gelatin (2, 89, 98) and cultured in cell culture media ranging from EBM-2 (46, 85, 117), medium-199 (38, 76, 98), to x-vivo-20 (25) as basal media and 20% fetal calf serum (9, 76), brain extract (9, 76), to commercial available single quotes of VEGF, insulin-like growth factor, and basic fibroblast growth factor (FGF) (46, 85, 116) as supplements. An identification criterion often used for EPCs in the culture of mononuclear cells for 4 or 7 days is the double-positive staining of EPCs for endothelial-specific lectin (*e.g.*, Ulex europaeus agglutini-1) and Dil-labeled acetylated low-density lipoproteins (LDL) (51, 76, 87). Early EPCs appear within 4–7 days of culture, are spindle-shaped, and express both endothelial (von Willebrand factor) and monocytic (CD14) markers (41). Late EPCs develop after 2–3 weeks of culture and have the characteristics of endothelial lineage-like cobblestone pattern (2, 9) and the expression of endothelial nitric oxide synthase (eNOS) (2).

Another approach to culture EPCs is a preplating procedure. This procedure claims to avoid contamination for early adherent cells such as differentiated monocytic or possible mature endothelial cells (97). After replating nonattached cells onto fibronectin in endothelial-specific medium, typical clusters of round cells centrally with spindle-shaped cells sprouting at the periphery appear. Some, but not all, of the cells inside the colony-forming unit are indeed double positive for acetylated LDL and lectin staining (38). For quantitative analysis the number of colonies finally appearing on the

culture plate are counted (colony forming units assay) (38). Nevertheless, one has to be aware that also the colonies formed by this procedure have to be considered as a mixed population of cells originating mainly from the lymphocyte/monocyte lineage (88, 114).

Mobilization of EPCs from the BM

The microenvironment of the BM, consisting of macrophages, fibroblasts, and endothelial cells, is very important for the mobilization and differentiation of stem/progenitor cells (57). When the body is developing new blood vessels (such as during the developmental stage), or affected by injury, EPCs are activated and migrate into the vascular zone of the BM where proliferation is increased. Various injuries such as ischemia, atherosclerotic lesions, traumatic wound, tumor angiogenesis (25, 37, 113), and myocardial infarction (54) cause the frequency of EPCs in the peripheral blood to increase up to 50-fold (25). At least in ischemia, this mechanism appears to be mediated by the hypoxia-inducible factor 1 α (HIF-1 α)-mediated upregulation of VEGF in the periphery, which plays a crucial role in vasculogenesis, angiogenesis, and EPC kinetics (75). Other molecules that have been shown to facilitate EPC mobilization from the BM to the periphery are angiopoietin-1, FGF1, stromal cell-derived factor-1 (SDF-1) (100), granulocyte colony-stimulating factor (CSF) (81), granulocyte-macrophage CSF (15), hydroxymethylglutaryl-coenzyme A synthase inhibitor (19, 66, 75), erythropoietin (EPO) (7), peroxisome proliferator-activated receptor- γ agonists (119), 17 β -Estradiol (E2) together with FGF2 (22), and reactive oxygen species (ROS) generated by nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) and Rac1 (74).

The principal mechanism of EPC mobilization from the BM seems to depend on the activation of eNOS in the presence of


several mobilizing factors such as VEGF (10), or placental growth factor (61). Gene targeting studies using either matrix metalloproteinase-2 (MMP-2) (14) or MMP-9 (42) knockout mice demonstrated that the presence of MMPs are crucial in ischemia-induced mobilization of EPCs and hence neo-vascularization. At the molecular/cellular level the following scenario for the mobilization is proposed (Fig. 1): Under steady state conditions EPCs reside in a niche of the BM, bound to stroma cells *via* adhesion molecules such as VCAM/VLA4 (57). Signal induced upregulation of MMP-9 results in the conversion of KitL from a membrane-bound molecule to a soluble survival (soluble KitL), conferring signals that enhances mobility of EPCs into a vascular-enriched niche favoring liberalization of the cells into the circulation (36).

Another model (50), based on the observation that stem cell release from the BM is regulated by circadian oscillations (13, 72), and the fact that a chemokine gradient of SDF-1 between the BM and the peripheral circulation plays a key role for stem cell mobilization (60), proposes the following mechanism: Activation of peripheral neurons and a subsequent release of norepinephrine leads to osteoblast suppression, thereby reducing the synthesis of SDF-1 in the BM. This generates a greater SDF-1 gradient between the BM and the circulation, thereby mobilizing the progenitor cells into the circulation (Fig. 2).

Endothelial Dysfunction

Impairment of endothelium-dependent vasomotion not only precedes the development of significant coronary artery stenosis, but has also been identified as a general phenomenon predicting future CV events in patients with CV risk factors (59, 92). There are several conditions that have been associated with endothelial dysfunction: (i) the presence of coronary risk factors like hypertension, hypercholesterolemia,

FIG. 1. A model for mobilization of circulating endothelial progenitor cells (EPCs) from the bone marrow by increased shear stress induced by exercise or by several different soluble molecules. Activation matrix metalloproteinases (MMP-9 and MMP-2) either directly or *via* the activation of NAD(P)H oxidase or endothelial nitric oxide synthase (eNOS) results in the release of soluble KitL. KitL confers signals enhancing mobility of EPCs. Along an SDF-1 gradient the EPCs are mobilized into the peripheral circulation. GM-CSF, granulocyte-macrophage colony-stimulating factor; NADPH, nicotinamide adenine dinucleotide phosphate. SDF-1, stromal cell-derived factor-1.






FIG. 2. Model describing the release of EPCs regulated by adrenergic neurons as described by Katayama and colleagues (50). After the activation of the adrenergic neuron by soluble factors like granulocyte CSF, norepinephrine (NE), and other yet unidentified factors mediate osteoblast (OB) suppression. This generates a greater SDF-1 gradient between the bone marrow and the circulation, thereby mobilizing the EPCs into the sinusoidal vessels.

diabetes mellitus, overweight, obesity, and cigarette smoking; (ii) a significant coronary artery disease (CAD), (iii) the presence of congestive heart failure (CHF), and (iv) the presence of inflammation and advanced age. More important, endothelial dysfunction can occur years before a makroangiopathy, for example, CAD, becomes evident. Therefore, endothelial dysfunction has been identified as an important treatment target.

Endothelial dysfunction and EPCs

As mentioned above, the maintenance of an intact and functional competent endothelial cell layer is very important for preventing CAD. Since mature endothelial cells possess only a limited regenerative capacity (20), there is growing interest in EPCs, especially in their role for the maintenance of endothelial integrity. Insufficient numbers of EPCs are related to endothelial dysfunction and adverse clinical events, suggesting that endothelial injury in the absence of sufficient repair by circulating progenitor cells promotes the development of vascular disease. But what is exactly the role of EPCs for the repair of a damaged endothelial cell layer? Currently, it is believed that mature endothelial cell and EPCs contribute to the rejuvenation of the endothelium (9, 97). It is thought that EPCs are attracted to the damaged endothelium by specific cell surface markers and after attaching to the neighboring endothelial cells fill in the gap and differentiate into a mature functional endothelial cell (90). This concept was supported by studies using transplantation of *ex vivo* expanded and labeled EPCs in a hindlimb mouse model (49). This first study clearly demonstrated an improved angiogenesis after cell transplantation, and an incorporation of the cells into the endothelial cell layer. Nevertheless, this concept of a direct involvement in endothelium repair by filling in the gap has been challenged in recent years (78). First hints for an indirect involvement of EPCs in endothelial regeneration came from studies demonstrating that EPCs secrete various cytokines such as SDF-1, VEGF and other factors enhancing the performance of mature endothelial cells in migration assays (110). Further, coculture experiments with endothelial cells and fibroblasts demonstrated that they enhanced tubulogen-

esis in a paracrine manner (99). In addition to this cell culture experiments, animal experiments using chimeric mice also showed that circulating EPCs do not participate directly in endothelial homeostasis and thus do not repair chronic, systemic endothelial dysfunction in young mice (78). Therefore, it is speculated at the moment that EPCs play an important role in regeneration and vasculogenesis either as cellular placeholder or as cytokine factories stimulating mature endothelial cells to proliferate and fill the gap in the damaged endothelial cell layer (Fig. 3).


Endothelial Dysfunction and Exercise

As mentioned above the maintenance of an intact endothelial cell layer is of great importance. In the last decade it became evident by several animal and clinical studies that exercise training is able to improve endothelial function in patients exhibiting an endothelial dysfunction [reviewed in Refs. (33, 64, 104)].

More than a decade ago it was observed that exercise training increases endothelium-dependent vasodilation in dog epicardial arteries (120). This observation was confirmed many times, and accumulating evidence suggest that exercise-induced activation of the NO/cGMP pathway is an important mechanism mediating beneficial vascular effects of exercise training. Numerous clinical studies in primary and secondary prevention of CV disease clearly revealed that mild to moderate exercise training in patients with endothelial dysfunction has the potential to correct endothelial dysfunction.

Hambrecht and colleagues were the first who prospectively assessed the effect of 4 weeks of exercise training on coronary vasomotion in patients with CAD (31). At 4 weeks follow up, acetylcholine-induced coronary vasoconstriction had declined and adenosine mediated flow reserve improved. Similar effects were seen in patients with CHF in response to an aerobic exercise training program (30). Besides systemic aerobic exercise training, also a 8-weeks resistance training of the forearm (68) and a lower limb exercise program (65) was able to improve local as well as systemic endothelial function in patients with CHF.

FIG. 3. Potential role of EPCs in maintaining an intact endothelial cell layer. EPCs bind to mature endothelial cells (EC) *via* specific cell surface marker (1). After binding to EC the EPC may have to possible pathways to repair the damage in the endothelial cell layer. First, it fills in the gap and differentiates into a mature endothelial cell (2) or second it secretes growth differentiation factors (3), which in turn stimulate mature endothelial cells (4) to proliferate and thereby closing the gap in the endothelial cell layer (5).




What are the molecular mechanisms behind these improvements in endothelial dysfunction? Experimental studies in animals and cell culture suggest that repetitive increases in shear stress enhance eNOS expression and eNOS phosphorylation, thereby contributing to an augmented nitric oxide (NO) bioavailability (16, 84). It has been shown in animals as well as in humans that shear stress-mediated activation of the phosphatidylinositol 3-kinase and subsequently of protein kinase A and B results in eNOS phosphorylation at Ser¹¹⁷⁷ with the consequence of an increase in eNOS activity and NO

production (Fig. 4) (29, 125). Besides a direct activation of eNOS in endothelial cells, exercise training also reduces the expression of NAD(P)H oxidase thereby reducing the generation of ROS (4). In conjunction with an increased expression of radical scavenger enzymes (63) this finally leads to an increased concentration of bioavailable NO (Fig. 4).

The beneficial effects of exercise training on endothelial function as described above depends on exercise intensity and time. As elegantly demonstrated in a study by Goto and colleagues only 12 weeks of moderate (50% VO₂max)

FIG. 4. Schematic diagram on the influence of exercise *via* increased laminar shear stress influences the concentration of NO bioavailability. Repetitive increase shear stress enhances eNOS phosphorylation at position serine-1177 *via* the activation of phosphatidylinositol 3-kinase (PI3K) and AKT. This activation leads to a higher concentration of NO. This increased NO concentration finally results in a smooth muscle-mediated dilation. The concentration of bioavailable NO is further stabilized by the reduced production of reactive oxygen species (ROS) due to downregulation of NAD(P)H oxidase. NO, nitric oxide.







FIG. 5. Schematic diagram on the influence of exercise, either as an acute bout of exercise or as exercise training programs on the mobilization of EPCs. Acute exercise leads to the mobilization of EPCs *via* an activation of NAD(P)H oxidase, leading to an increase of ROS. On the other hand long-term exercise training up-regulates eNOS and radical scavenger enzymes, leading to an elevation of bioavailable NO. Both mechanisms increase the concentration of circulating EPCs finally resulting in repair of damaged endothelial cells and angiogenesis and vasculogenesis.

exercise augmented endothelium-dependent vasodilation, whereas mild (25% $\text{VO}_{2\text{max}}$)- or high-intensity (75% $\text{VO}_{2\text{max}}$) exercise showed no effect (27). The reason for this dosage effect is probably due to the rate of ROS production. High-intensity exercise increases plasma concentrations of 8-hydroxy-2'-deoxyguanosine and serum concentrations of malondialdehyde-modified LDL, whereas moderate exercise tended to decrease both indices of oxidative stress. However, in a recent study from Tjonna *et al.* the authors clearly demonstrated in patients with metabolic syndrome that high in-

tensity interval training (95% $\text{VO}_{2\text{max}}$) was superior to moderate exercise with respect to endothelial function (108).

There is increasing evidence that ROS are not only toxic, but also modifies gene expression. As demonstrated by Gomez-Cabrera, the inhibition of xanthine oxidase by allopurinol also prevented the nuclear factor-kappaB mediated elevation in antioxidative enzymes like manganese superoxide dismutase (MnSOD) or glutathione peroxidase (GPX) (26) (Figs. 5 and 6). Therefore, exercise itself can be considered also as an antioxidant.

FIG. 6. Possible signaling pathway of acute and regular exercise-induced angiogenesis and maintenance of an intact endothelial cell layer. Partially modified from Maulik (71).



Exercise and EPC Mobilization

Exercise training as a nonpharmacologic intervention has the potency to increase the number and function of circulating EPCs. This concept is based on the findings that exercise intervention programs are able to improve endothelial function in patients with CAD and chronic heart failure as shown in the previous chapter, and that EPCs are thought to participate in the repair of damaged endothelial cell layers (52, 111). Both mesenchymal stem cells and EPCs can be mobilized from the BM by ischemia, neurohormonal factors (*e.g.*, VEGF, placental growth factor), and exercise. It is still a matter of continuing debate whether training-induced flow changes or ischemia induction is required to stimulate EPC release. In two clinical studies we demonstrated that an increase in circulating EPCs was only achieved in response to exercise-induced ischemia (2, 89). Other authors showed exercise-related EPC increase also in the absence of ischemia (Table 2). Prolonged strenuous exercise (half-marathon, marathon or a spartathlon), however, showed no change or a significant increase in circulating progenitor cells (Table 2). What are possible explanations for these discrepancy among the different studies? Several reasons may account for these differences:

1. Subjects investigated in the studies. Looking at Table 2 it is evident that different study populations were analyzed in the studies ranging from healthy subjects (39, 86, 115) to patients with CAD (2, 58, 77) peripheral artery occlusion disease (89, 95) and patients requiring dialysis (69).
2. Different training conditions—intensity and time. Intensity of the training program varied significantly ranging from $2 \times$ /day walking for 10 min (69) to training several times per day at 60%–80% of VO_2max (39, 58, 89). In addition the training program lasted from 4 weeks (58, 89) up to 6 month (69).
3. Age of the subjects. At least in one study only school children were analyzed (118), whereas most other studies investigated middle-aged (39, 95) or older subjects (3, 39, 95).

With respect to the molecular mechanisms regulating the exercise-mediated mobilization of EPCs, we have to discriminate between the effect of an acute bout of exercise and a regular physical exercise program over a certain period. In the setting of acute exercise, ROS seems to play an important role, whereas in the situation of regular exercise training, NO is the major molecule regulating EPC mobilization (Fig. 5).

Acute Exercise and EPC Mobilization

As pointed out above and summarized in Table 2, several studies clearly demonstrated that an acute bout of exercise in either patients with CAD (2) or healthy subjects (77, 115, 122) resulted in the mobilization of EPCs from the BM. A consistent finding in the literature is that metabolic genes increase transiently after an acute bout and returning to near pre-exercise levels 24 h after the end of exercise (79, 80). Besides the induction of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha, an important regulator of mitochondrial biogenesis, HIF-1, is activated after a single exercise bout (Fig. 6) (67). HIF-1 is a heterodimer consisting of the constitutively expressed HIF-1 β protein and the HIF-1 α protein. HIF-1 responsive genes include VEGF, SDF-1, and

EPO, all important molecules inducing EPC mobilization (Fig. 6) (10, 35). Based on a recently published animal study by the group of Dr. Brandes in Frankfurt, Germany, it is reasonable to assume that ROS generated by the NAD(P)H oxidase are essential for hypoxia or EPO-induced mobilization of EPCs (94). In that study the authors used C57Bl6 and Nox2 knockout mice. The exposure of these mice to hypoxia or EPO resulted in a significant mobilization in the wild-type animals but failed in the Nox2 knockout mice. Mechanistically, they proposed the following mechanism: EPO binds to the EPO receptor, which then dimerizes and allows binding of Janus-kinase 2. Janus-kinase 2 creates SH2 binding sites by phosphorylating tyrosine residues at the receptor. Phosphorylation of the receptor activates Rac1 and phosphatidylinositol 3-kinase, which leads to the assembly of Nox2-containing NADPH oxidase subsequently producing superoxide anions. Superoxide anions are dismutated to hydrogen peroxide (H_2O_2), which inactivates the protein-tyrosine phosphatase SHP-2. Meanwhile, STAT5 binds to the SH2 domains of the EPO-receptor, where it gets phosphorylated, dimerizes, and eventually translocates to the nucleus to induce transcription of target genes, leading to EPC mobilization. The importance of Nox2-based NAD(P)H oxidase for the mobilization of stem/progenitor cells was also evident in a hind-limb ischemia model (109). In this model the induction of a hind-limb ischemia in C57Bl6 mice resulted in a significant increase of Nox2 expression in BM, which is associated with an increase in circulating stem/progenitor cells. Mice lacking Nox2 showed a significant reduction of ischemia-induced flow recovery, ROS levels in BM cells, as well as EPC mobilization from the BM. This defect in Nox2-deficient mice could be rescued by the transplantation of BM from normal mice.

Other factors possibly involved in the mobilization of EPCs after an acute bout of exercise are certain growth factors such as VEGF, SDF-1, or granulocyte CSF. Our group could demonstrate that in patients with symptomatic CAD a single maximal exercise stress test a significant rise in VEGF could be documented, which exhibited a positive correlation to the amount of mobilized EPCs (2).

It is recognized now a days that in addition to induce cellular damage, ROS also serve as secondary intracellular messengers and impact the overall redox status of a cell. Importantly, the intracellular redox environment has a critical role in controlling apoptosis, proliferation, self-renewal, senescence, and differentiation (5, 56). Although excess amount of ROS is toxic to EPCs and stem/progenitor cells, optimal levels of ROS, determined by a balance of ROS generating and antioxidative enzymes, are required for normal EPC function in neovascularization. What are possible sources for the elevated ROS concentration after an acute bout of exercise? As already discussed above, the NAD(P)H oxidase seems to be an important ROS source. The Nox2-based NAD(P)H oxidase is also localized in the BM, where its activation seems to be essential for EPC mobilization (94, 109). An other potential source is the electron transport chain of mitochondria (18).

Regular Exercise Training and EPC Mobilization

As discussed previously, exercise training has the potency to increase the concentration of bioavailable NO. This can be achieved either by increasing the expression and activity of eNOS (29, 58) or by decreasing the concentration of ROS (4).

TABLE 2. SUMMARY OF HUMAN STUDIES ANALYZING THE IMPACT OF EXERCISE ON THE AMOUNT OF CIRCULATING PROGENITOR CELLS

Study	Study population	Description of study and exercise protocol	Progenitor cell definition	Study outcome
<i>Single exercise bout</i> Adams <i>et al.</i> (2)	28 CAD points with or without exercise-induced ischemia and 11 healthy controls	Maximal stress test. Follow-up of cell concentration for up to 144 h	Flow cytometry: CD34 ⁺ /KDR ⁺ Cell culture: Ac-LDL ⁺ /lectin ⁺	Time-dependent increase in ischemic points (max. after 24–48 h), no change in nonischemic points and controls
Rehman <i>et al.</i> (86)	22 healthy subjects	Symptom-limited treadmill or bicycle exercise test. Blood samples were collected 5 to 10 min after the test.	Flow cytometry: AC133 ⁺ /VECadherin ⁺ or AC133 ⁺ /VECadherin ⁻	Significant increase of both cell types after exercise test
Shaffer <i>et al.</i> (95)	9 young healthy subjects, 13 older healthy subjects, 15 older subjects with PAOD	Blood was collected from subjects before and 20 min after a graded exercise.	Flow cytometry: CD34 ⁺ /KDR ⁺ or CD133 ⁺ /KDR ⁺	Level of EPCs tended to increase in all subjects after exercise.
Van Craenenbroeck <i>et al.</i> (115)	25 healthy subjects	Symptom-limited cardiopulmonary test. Blood was collected 10 min after peak exercise.	Flow cytometry: CD34 ⁺ /KDR ⁺	Significant increase of EPCs after exercise test
<i>Training program</i> Laufs <i>et al.</i> (58)	19 points with stable CAD	Moderate exercise training for 28 days at 60%–80% VO ₂ max, ergometer and strength training	Flow cytometry: CD34 ⁺ /KDR ⁺	Significant increase of EPCs after 28 days of an exercise program
Steiner <i>et al.</i> (101)	20 CAD points for training 20 age-matched sedentary controls	12 weeks training, 3 × per week individual training plus 2 endurance running sessions	Flow cytometry: CD34 ⁺ /CD133 ⁺ /KDR ⁺	Augmentation of circulating EPCs in the training group, no change in the sedentary control group
Sandri <i>et al.</i> (89)	18 points with ischemic PAOD 18 points with nonischemic PAOD 31 points with CAD	4 weeks, 6 × per day under close supervision in hospital. Randomization into a exercise training or sedentary group	Flow cytometry: CD34 ⁺ /KDR ⁺	Exercise training augments the amount of circulating progenitor cells, but ischemia seems to be necessary. No effect was observed in sedentary controls.

(continued)

TABLE 2. (CONTINUED)

Study	Study population	Description of study and exercise protocol	Progenitor cell definition	Study outcome
Hoetzer <i>et al.</i> (39)	10 healthy middle-aged or older men	3-month home-based moderate aerobic training, 5–7 days/week, 40–50 min/day, 60%–75% VO ₂ max. Measurement before and after training period	Cell culture–CFU	Significant increase in CFU after 3 month
Paul <i>et al.</i> (77)	50 points with CAD	The points completed a 36-session cardiac rehabilitation program	Flow cytometry: CD133 ⁺ /KDR ⁺ Cell culture–CFU	Increase in EPCs either measured by flow cytometry or CFU after finishing the rehabilitation program
Walther <i>et al.</i> (118)	182 healthy children	Randomization into intervention class (daily exercise lessons) or control class (school sports twice weekly) for 1 year	Flow cytometry: CD34 ⁺ /KDR ⁺ /CD45 ^{low}	Significant increase in progenitor cells in the intervention class but not in the control class after 1 year
Manfredini <i>et al.</i> (69)	32 dialysis patients	Randomization into exercise (2 × /day 10 min home-walking at moderate intensity) and sedentary control. Cell measurement at begin and after 6 month	Flow cytometry: CD34 ⁺ /CD133 ⁺ /KDR ⁺ Cell culture–CFU	Increase of CFU in training group but no change in CD34 ⁺ /CD133 ⁺ /KDR ⁺ cell number. No change in the control group
<i>Extreme conditions</i> Bonsignore <i>et al.</i> (12)	8 subjects running a marathon and 8 subjects running a half-marathon	Blood was collected before, after finishing the race and at the morning posttrace.	Flow cytometry: CD34 ⁺	No change in CD34 ⁺ cells after finishing the race, but a significant decrease in cell concentration the morning after the race
Adams <i>et al.</i> (3)	68 advanced-age marathon runners	Blood was collected before and after finishing the marathon race.	Flow cytometry: CD133 ⁺ /KDR ⁺	No change of EPC concentration was observed comparing before and after the race.
Möbius-Winkler <i>et al.</i> (73)	18 healthy young men	4h cycling at 70% of IAT. Blood sampling at beginning, during, and after finishing cycling.	Flow cytometry: CD34 ⁺ /KDR ⁺ or CD133 ⁺ /KDR ⁺	EPCs showed a significant time-dependent increase with a maximum after 210/240 min.
Goussetis <i>et al.</i> (28)	10 volunteer athletes	Blood was drawn before and after a 246-km foot race (Spartathlon).	Cell culture–CFUs	EPCs increased significantly in the peripheral blood at the end of the race.

Ac-LDL, acetylated low-density lipoprotein; CAD, coronary artery disease; PAOD, peripheral artery occlusion disease.

Exercise training, EPC, and NOS

That the eNOS plays a central role for the exercise-mediated increase in EPCs was first documented in eNOS knockout mice by Laufs and colleagues *et al.* (58). In these experiments voluntary running in a running wheel over 28 days resulted in a significant upregulation of circulating progenitor cells, defined as Sca-1⁺/KDR⁺ cells, only in wild-type mice, but was significantly blunted in eNOS knockout mice. The same effect could be mimicked in wild-type mice treated with the specific NOS inhibitor L-NG-Nitroarginine methyl ester (58).

How can we explain the NO-dependent exercise-induced mobilization of EPC? In several studies it could be demonstrated that exercise increases the concentration of NO (29), which in turn can activate MMP-9 in BM (47), leading to enhanced mobilization of progenitor cells as depicted above. As soon as the EPCs are circulating, the most important factors for tissue engraftment of the mobilized cells are the local concentration of SDF-1 α , and its cell receptor CXCR-4 (11). This notion is further supported by the observation that mice lacking CXCR4 die *in utero* due to defects in vascular development (105). Although the animal data make shear-stress-induced NO generation a likely mechanism for NO-mediated EPC mobilization, animal experiments with ischemic exercise are still lacking. Therefore, the above-mentioned controversy still awaits experimental resolution.

Antioxidative enzyme, EPC, and exercise training

Stem cells express high levels of genes that are associated with DNA repair and protection from stress (45, 83). It has been shown that EPCs have lower levels of basal and stress-induced ROS than mature endothelial cells due to a high expression of catalase, MnSOD, extracellular superoxide dismutase (ecSOD), and GPX-1 (17, 34). Importantly, the collective inhibition of catalase, MnSOD, and GPX-1 increases levels of ROS in EPC and impair survival and function of these cells (17).

ROS and especially H₂O₂ play an important part in vascular oxidative stress and exert several deleterious effects in the CV system such as increased smooth muscle proliferation, stimulation of inflammation, promotion of atherosclerotic process, and alteration in vascular tone (8). Beside all these effects, it could recently be demonstrated that H₂O₂ also seems to inhibit exercise-induced increase of circulating EPCs (103). In this elegant study, Suvorava and colleagues used a transgenic animal model overexpressing catalase under the control of a Tie-2 promoter and a voluntary exercise training regime with excess to running wheels. They could clearly demonstrate that exercise training was only efficient in EPC mobilization in mice with a catalase overexpression. As molecular explanation the authors speculated that H₂O₂ diffuse from the vascular niche to the stem cell niche in the BM, where it may have an inhibitory effect on MMP-9, the essential molecule for EPC mobilization. That the expression of radical scavenger enzymes plays an important role for reparative neovascularization or angiogenesis was also shown in two other transgenic animal models (24, 53). In GPX-1-deficient mice ischemia-induced angiogenesis was significantly impaired (24). Analyzing the EPCs from these mice it became evident that they exhibit an impaired angiogenic capacity *in vivo* and *in vitro* and increased

susceptibility to oxidative stress- and ROS-induced cell death *in vitro* (24). These findings could be confirmed in mice lacking the expression of ecSOD, the major anti-oxidative enzyme in the extracellular space (70, 102). Also in these mice, EPCs in both peripheral and BM are reduced compared to wild-type animals, and the ischemia-induced neovascularization is significantly impaired. This defective neovascularization could be rescued by transplantation of BM from wild-type animals. Collectively, these data suggest that an imbalance in ROS can contribute to EPC dysfunction and their lack of angiogenic function.

Does exercise training has any impact also on the antioxidative system? Acute aerobic and anaerobic exercise training increases vascular oxidative stress and subsequent damage to cellular proteins, lipids, and nucleic acids as well as changes to the glutathione system (48). While acute and exhaustive exercise leaves little time for cellular adaptation reactions based on altered gene expression, these adaptation reactions have been shown to occur in moderate exercise training for several weeks, for example, the upregulation of eNOS above. Interestingly, induction of eNOS expression by exercise training was shown to be followed by an induction of ecSOD protein (23).

Conclusion

The beneficial effects of exercise training on vascular function are well established: long-term physical activity significantly improves endothelium-dependent vasodilation in response to flow or acetylcholine infusion. An important cellular system for maintaining an intact endothelial cell layer as well as for the generation of new blood vessel by angiogenesis or vasculogenesis is EPCs. These cells are liberated in increasing concentration from the BM as a result of exercise—acute exercise as well as long-term exercise training. Based on the current data available in the literature, it seems that the molecular mechanisms regulating the exercise-induced mobilization of EPCs are different in acute exercise and exercise training. In acute exercise the increased generation of ROS *via* the NAD(P)H oxidase system seems to trigger the release of the cells from the BM, whereas in chronic exercise training the concentration of bioavailable NO is the major molecule. These two imported system are also influenced by the expression of radical scavenger enzymes like ecSOD and GPX-1. Still, a matter of debate is the exact function of the EPCs (direct mechanisms to repair the endothelial cell layer or paracrine effects) and the exact cellular definition *via* cell surface marker of EPCs.

References

1. Adams V, Challan GA, Zuba-Surma E, Ulrich H, Vereb G, and Tarnok A. Where new approaches can stem from: focus on stem cell identification. *Cytometry* 75: 1–3, 2009.
2. Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, and Hambrecht R. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. *Arterioscler Thromb Vasc Biol* 24: 684–690, 2004.
3. Adams V, Linke A, Breuckmann F, Leineweber K, Erbs S, Kränkel N, Bröcker-Preuss M, Woitek F, Erbel R, Heusch G, Hambrecht R, Schuler G, and Möhlenkamp S. Circulating progenitor cells decrease immediately after marathon race in

- advanced-age marathon runners. *Eur J Cardiovasc Prev Rehabil* 15: 602–607, 2008.
4. Adams V, Linke A, Kränkel N, Erbs S, Gielen S, Möbius-Winkler S, Gummert JF, Mohr FW, Schuler G, and Hambrecht R. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. *Circulation* 111: 555–562, 2005.
 5. Adler V, Yin Z, Tew KD, and Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. *Oncogene* 18: 6104–6111, 1999.
 6. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fändrich F, Siebert R, Cooke JP, and Dimmeler S. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. *Circ Res* 100: 581–589, 2007.
 7. Anagnostou A, Lee ES, Kessimian N, Levinson R, and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. *Proc Natl Acad Sci USA* 87: 5978–5982, 1990.
 8. Ardanaz N and Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. *Exp Biol Med* 231: 237–251, 2006.
 9. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 275: 964–967, 1997.
 10. Asahara T, Takahashi T, and Masuda H. VEGF contributes to postnatal neovascularization by mobilizing bone-marrow endothelial progenitor cells. *EMBO J* 18: 3964–3972, 1999.
 11. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, and Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. *Lancet* 362: 697–703, 2003.
 12. Bonsignore MR, Morici G, Santoro A, Pagano M, Cascio L, Bonanno A, Abate P, Mirabella F, Profita M, Insalaco G, Giola M, Vignola AM, Majolino I, Testa U, and Hogg JC. Circulating hematopoietic progenitor cells in runners. *J Appl Physiol* 93: 1691–1697, 2002.
 13. Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, Player D, Nakagawa T, Afzal A, Kielczewski J, Sochacki A, Hasty S, Calzi SL, Kim S, Duclas SK, Segal MS, Guberski DL, Esselman WJ, Boulton ME, and Grant MB. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. *J Exp Med* 206: 2897–2906, 2009.
 14. Cheng XW, Kuzuya M, Nakamura K, Maeda K, Tsuzuki M, Kim W, Sasaki T, Liu Z, Inoue N, Kondo T, Jin H, Numaguchi Y, Okumura K, Yokota M, Iguchi A, and Murohara T. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. *Circ Res* 100: 904–913, 2007.
 15. Cho HJ, Kim HS, Lee MM, Kim DH, Yang HJ, Hur J, Hwang KK, Seil O, Choi YJ, Chae IH, Oh BH, Choi YS, Walsh K, and Park YB. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate re-endothelialization and reduce vascular inflammation after intravascular radiation. *Circulation* 108: 2918–2925, 2003.
 16. Davis ME, Cai H, McCann L, Fukai T, and Harrison DG. Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training. *Am J Physiol Heart Circ Physiol* 284: H1449–H1453, 2003.
 17. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, and Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. *Blood* 104: 3591–3597, 2004.
 18. Di Meo S and Venditti P. Mitochondria in exercise-induced oxidative stress. *Biol Signals Recept* 10: 125–140, 2001.
 19. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, and Zeiher A. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. *J Clin Invest* 108: 391–397, 2001.
 20. Dimmeler S and Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? *J Mol Med* 82: 671–677, 2004.
 21. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, and Greaves MF. Expression of the CD34 gene in vascular endothelial cells. *Blood* 75: 2417–2426, 1990.
 22. Fontaine V, Filipe C, Werner N, Gourdy P, Billon A, Garmy-Susini B, Bouchet L, Bayard F, Prats H, Doetschman T, Nickenig G, and Arnal JF. Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on re-endothelialization and endothelial progenitor cell mobilization. *Am J Pathol* 169: 1855–1862, 2006.
 23. Fukui T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, and Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. *J Clin Invest* 105: 1631–1639, 2000.
 24. Galasso G, Schiekofer S, Sato K, Shibata R, Handy DE, Ouchi N, Leopold JA, Loscalzo J, and Walsh K. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. *Circ Res* 98: 254–261, 2006.
 25. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, and Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2⁺ AC133⁺ endothelial precursor cells. *Circ Res* 88: 167–174, 2001.
 26. Gomez-Cabrera MC, Domenech E, and Vina J. Moderate exercise is an antioxidant: upregulation of antioxidant genes by training. *Free Radic Biol Med* 44: 126–131, 2008.
 27. Goto C, Higashi Y, Kimura M, Noma K, Hara K, Nakagawa K, Kawamura M, Chayama K, Yoshizumi M, and Nara I. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. *Circulation* 108: 530–535, 2003.
 28. Goussetis E, Spiropoulos A, Tsironi M, Skenderi K, Margeli A, Graphakos S, Baltopoulos P, and Papassotiropoulos I. Spartathlon, a 246 kilometer foot race: effects of acute inflammation induced by prolonged exercise on circulating progenitor reparative cells. *Blood Cells Mol Dis* 42: 294–299, 2009.
 29. Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, Baither Y, Gielen S, Gummert JF, Mohr FW, and Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. *Circulation* 107: 3152–3158, 2003.
 30. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, and Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. *Circulation* 98: 2709–2715, 1998.
 31. Hambrecht R, Wolff A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, and Schuler G. Effect of exercise on coronary

- endothelial function in patients with coronary artery disease. *N Engl J Med* 342: 454–460, 2000.
32. Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring HJ, Niethammer D, and Kuci S. Biology and plasticity of CD133+ hematopoietic stem cells. *Ann NY Acad Sci* 996: 141–151, 2003.
 33. Haram PM, Kemi OJ, and Wisloff U. Adaptation of endothelium to exercise training: insights from experimental studies. *Front Biosci* 13: 336–346, 2008.
 34. He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM, Oberley LW, and Katusic ZS. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. *Arterioscler Thromb Vasc Biol* 24: 2021–2027, 2004.
 35. Heesch C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher A, and Dimmeler S. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. *Blood* 102: 1340–1346, 2003.
 36. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, and Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell* 109: 625–637, 2002.
 37. Henrich D, Hahn P, Wahl M, Wilhelm K, Dernbach E, Dimmeler S, and Marzi I. Serum derived from multiple trauma patients promotes the differentiation of endothelial progenitor cells in vitro: possible role of transforming growth factor- β 1 and vascular endothelial growth factor165. *Shock* 21: 13–16, 2004.
 38. Hill JM, Zalos G, Halcox JPI, Schenke WH, Waclawiw MA, Quyyumi AA, and Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 348: 593–600, 2003.
 39. Hoetzer GL, Van Guilder GP, Irmiger HM, Keith RS, Stauffer BL, and DeSouza CA. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. *J Appl Physiol* 102: 847–852, 2007.
 40. Hristov M, Erl W, and Weber PC. Endothelial progenitor cells: isolation and characterization. *Trends Cardiovasc Med* 13: 201–206, 2003.
 41. Hristov M and Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. *J Cell Mol Med* 8: 498–508, 2004.
 42. Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, Lin FY, Lo WY, Wu TC, Sata M, Chen JW, and Lin SJ. Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. *Arterioscler Thromb Vasc Biol* 29: 1179–1184, 2009.
 43. Ingram DA, Caplice NM, and Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. *Blood* 106: 1525–1531, 2005.
 44. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, and Yoder MC. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. *Blood* 104: 2752–2760, 2004.
 45. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, and Lemischka IR. A stem cell molecular signature. *Science* 298: 601–604, 2002.
 46. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayash S, Silver M, Isner JM, and Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. *Circulation* 105: 732–738, 2002.
 47. Iwakura A, Shastri S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T, and Losordo DW. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. *Circulation* 113: 1605–1614, 2006.
 48. Ji LL. Antioxidants and oxidative stress in exercise. *Proc Soc Exp Biol Med* 222: 283–292, 1999.
 49. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner J, and Asahara T. Transplantation of *ex vivo* expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci USA* 97: 3422–3427, 2000.
 50. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, and Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 124: 407–421, 2006.
 51. Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, Schoen FJ, Atala A, Soker S, Bischoff J, and Mayer JE. Functional small-diameter neovessels created using endothelial progenitor cells expanded *ex vivo*. *Nat Med* 7: 1035–1040, 2001.
 52. Kawamoto A and Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. *Trends Cardiovasc Med* 18: 33–37, 2008.
 53. Kim HW, Lin A, Guldberg RE, Ushio-Fukai M, and Fukai T. Essential role of extracellular sod in reparative neovascularization induced by hindlimb ischemia. *Circ Res* 101: 409–419, 2007.
 54. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, and Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 7: 430–436, 2001.
 55. Krenning G, Dankers PYW, Drouven JW, Waanders F, Franssen CFM, van Luyn MJA, Harmsen MC, and Popa ER. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. *Am J Physiol Renal Physiol* 296: F1314–F1322, 2009.
 56. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, Kraemer RT, Mirza UA, Chait BT, Burk SC, and Quilliam LA. Redox regulation of cell signalling. *Nature* 381: 380–381, 1996.
 57. Lapidot T and Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. *Exp Hematol* 30: 973–981, 2002.
 58. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Mische E, Böhm M, and Nickenig G. Physical training increases endothelial progenitor cells, inhibition of neointima formation, and enhances angiogenesis. *Circulation* 109: 220–226, 2004.
 59. Lerman A and Zeiher AM. Endothelial function: cardiac events. *Circulation* 111: 363–368, 2005.
 60. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, and Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. *Exp Hematol* 30: 440–449, 2002.

61. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, and Young PP. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. *FASEB J* 20: 1495–1497, 2006.
62. Lin Y, Weisdorf DJ, Solovey A, and Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. *Eur J Clin Invest* 105: 71–77, 2000.
63. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Möbius-Winkler S, Schubert A, Schuler G, and Hambrecht R. Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. *Circulation* 111: 1763–1770, 2005.
64. Linke A, Erbs S, and Hambrecht R. Effects of exercise training upon endothelial function in patients with cardiovascular disease. *Front Biosci* 13: 424–432, 2008.
65. Linke A, Schoene N, Gielen S, Hofer J, Erbs S, Schuler G, and Hambrecht R. Endothelial dysfunction in patients with chronic heart failure: systemic effects of lower-limb exercise training. *J Am Coll Cardiol* 37: 392–397, 2001.
66. Llevadot J, Murasawa S, Kureishi S, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, and Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. *J Clin Invest* 108: 399–405, 2001.
67. Lundby C, Gassmann M, and Pilegaard H. Regular endurance training reduces the exercise induced HIF-1 α and HIF-2 α mRNA expression in human skeletal muscle in normoxic conditions. *Eur J Appl Physiol* 96: 363–369, 2006.
68. Maiorana A, O'Driscoll G, Dembo L, Cheetham C, Goodman C, Taylor R, and Green D. Effect of aerobic and resistance exercise training on vascular function in heart failure. *Am J Physiol Heart Circ Physiol* 279: H1999–H2005, 2000.
69. Manfredini F, Rigolin GM, Malagoni AM, Catizone L, Mandini S, Soffritti O, Mauro E, Soffritti S, Boari S, Cuneo A, Zamboni P, and Manfredini R. Exercise training and endothelial progenitor cells in hemodialysis patients. *J Int Med Res* 37: 534–540, 2009.
70. Marklund SL. Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. *Biochem J* 222: 649–655, 1984.
71. Maulik N. Redox signaling in angiogenesis. *Antioxid Redox Signal* 4: 805–815, 2002.
72. Mendez-Ferrer S, Lucas D, Battista M, and Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* 452: 442–447, 2008.
73. Möbius-Winkler S, Hilberg T, Menzel K, Golla E, Burman A, Schuler G, and Adams V. Time-dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individuals. *J Appl Physiol* 107: 1943–1950, 2009.
74. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, and Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. *Cardiovasc Res* 71: 236–246, 2006.
75. Murasawa S and Asahara T. Endothelial progenitor cells for vasculogenesis. *Physiology* 20: 36–42, 2005.
76. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, and Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J Clin Invest* 105: 1527–1536, 2000.
77. Paul JDM, Powell TMM, Thompson MB, Benjamin MM, Rodrigo MM, Carlow AB, Annavejhal VB, Shiva SP, Dejam AM, Gladwin MTM, McCoy JPP, Zalos GR, Press BM, Murphy MR, Hill JMM, Csako GM, Waclawiw MAP, and Cannon RO. Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation. *J Cardiopulm Rehabil Prev* 27: 65–73, 2007.
78. Perry TE, Song M, Despres DJ, Kim SM, San H, Yu ZX, Raghavachari N, Schnermann J, Cannon RO, and Orlic D. Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction. *Cardiovasc Res* 84: 317–325, 2009.
79. Pilegaard H, Ordway GA, Saltin B, and Neufer PD. Transcriptional regulation of gene expression in human skeletal muscle during recovery from exercise. *Am J Physiol Endocrinol Metab* 279: E806–E814, 2000.
80. Pilegaard H, Saltin B, and Neufer PD. Exercise induces transient transcriptional activation of the PGC-1 + 1 gene in human skeletal muscle. *J Physiol* 546: 851–858, 2003.
81. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, and Cannon RO, III. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 25: 296–301, 2005.
82. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, and Delilieri GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. *Br J Haematol* 115: 186–194, 2001.
83. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, and Melton DA. “Stemness”: transcriptional profiling of embryonic and adult stem cells. *Science* 298: 597–600, 2002.
84. Ranjan V, Xiao Z, and Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. *Am J Physiol* 269: H550–H555, 1995.
85. Rehman J, Li J, Orschell CM, and March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. *Circulation* 107: 1164–1169, 2003.
86. Rehman J, Li J, Parvathaneni L, Karlsson G, Panchal VR, Temm CJ, Mahenthiran J, and March KL. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. *J Am Coll Cardiol* 43: 2314–2318, 2004.
87. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, and Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest* 109: 337–346, 2002.
88. Rohde E, Bartmann C, Schallmoser K, Reinisch A, Lanzer G, Linkesch W, Guelly C, and Strunk D. Immune cells mimic the morphology of endothelial progenitor colonies *in vitro*. *Stem Cells* 25: 1756–1752, 2007.
89. Sandri M, Adams V, Gielen S, Linke A, Lenk K, Krankel N, Lenz D, Erbs S, Scheinert D, Mohr FW, Schuler G, and Hambrecht R. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. *Circulation* 111: 3391–3399, 2005.
90. Sata M. Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. *Trends Cardiovasc Med* 13: 249–253, 2003.
91. Sauter B, Foedinger D, Sterniczky B, Wolff K, and Rappersberger K. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells: differential expression of CD31, CD34, and type iv collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma *in situ*. *J Histochem Cytochem* 46: 165–176, 1998.

92. Schächinger V, Britten MB, and Zeiher A. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 101: 1899–1906, 2000.
93. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, and Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. *Circulation* 111: 2981–2987, 2005.
94. Schroder K, Kohnen A, Aicher A, Liehn EA, Buchse T, Stein S, Weber C, Dimmeler S, and Brandes RP. NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. *Circ Res* 105: 537–544, 2009.
95. Shaffer RG, Greene S, Arshi A, Supple G, Bantly A, Moores JS, Parmacek MS, and Mohler ER, III. Effect of acute exercise on endothelial progenitor cells in patients with peripheral arterial disease. *Vasc Med* 11: 219–226, 2006.
96. Sharpe EE, Teleron AA, Li B, Price J, Sands MS, Alford K, and Young PP. The origin and *in vivo* significance of murine and human culture-expanded endothelial progenitor cells. *Am J Pathol* 168: 1710–1721, 2006.
97. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MAS, Storb RF, and Hammond WP. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 92: 362–367, 1998.
98. Shintani S, Murohara T, Ikeda H, Ueno T, Homma T, Katoh A, Sasaki K, Shimada T, Oike Y, and Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. *Circulation* 103: 2776–2779, 2001.
99. Sieveking DP, Buckle A, Celermajer DS, and Ng MKC. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. *J Am Coll Cardiol* 51: 660–668, 2008.
100. Smadja DM, Bieche I, Uzan G, Bompais H, Muller L, Boisson-Vidal C, Vidaud M, Aiach M, and Gaussem P. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis *in vitro* with upregulation of the SDF-1/CXCR4 system. *Arterioscler Thromb Vasc Biol* 25: 2321–2327, 2005.
101. Steiner S, Niessner A, Ziegler S, Richter B, Seidinger D, Pleiner J, Penka M, Wolzt M, Huber K, Wojta J, Minar E, and Kopp CW. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. *Atherosclerosis* 181: 305–310, 2005.
102. Stralin P, Karlsson K, Johansson BO, and Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. *Arterioscler Thromb Vasc Biol* 15: 2032–2036, 1995.
103. Suvorava T, Kumpf S, Rauch BH, Dao VT-V, Adams V, and Kojda G. Hydrogen peroxide inhibits exercise-induced increase of circulating stem cells with endothelial progenitor capacity. *Free Radic Res* 44: 199–207, 2010.
104. Tabet JY, Meurin P, Ben Driss A, Weber H, Renaud N, Grosdemouge A, Beauvais F, and Cohen-Solal A. Benefits of exercise training in chronic heart failure. *Arch Cardiovasc Dis* 102: 721–730, 2009.
105. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa Si, Kishimoto T, and Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature* 393: 591–594, 1998.
106. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, and Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation* 106: 2781–2786, 2002.
107. Thijssen DHJ, Vos JB, Verseyden C, van Zonneveld AJ, Smits P, Sweep FCGJ, Hopman MTE, and de Boer HC. Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training. *Aging Cell* 5: 495–503, 2006.
108. Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM, Loennechen JP, Al-Share QY, Skogvoll E, Slordahl SA, Kemi OJ, Najjar SM, and Wisloff U. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. *Circulation* 118: 346–354, 2008.
109. Urao N, Inomata H, Razvi M, Kim HW, Wary K, McKinney R, Fukai T, and Ushio-Fukai M. Role of Nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. *Circ Res* 103: 212–220, 2008.
110. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, and Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. *J Mol Cell Cardiol* 39: 733–742, 2005.
111. Urbich C and Dimmeler S. Endothelial progenitor cells. Characterization and role in vascular biology. *Circ Res* 95: 343–353, 2004.
112. Urbich C and Dimmeler S. Endothelial progenitor cells: functional characterization. *Trends Cardiovasc Med* 14: 318–322, 2004.
113. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher A, and Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. *Circulation* 108: 2511–2516, 2003.
114. van Beem RT, Noort WA, Voermans C, Kleijer M, ten Brinke A, van Ham SM, van der Schoot CE, and Zwaginga JJ. The presence of activated CD4+ T cells is essential for the formation of colony-forming unit-endothelial cells by CD14+ Cells. *J Immunol* 180: 5141–5148, 2008.
115. Van Craenenbroeck EMF, Vrints CJ, Haine SE, Vermeulen K, Goovaerts I, Van Tendeloo VFI, Hoymans VY, and Conraads VMA. A maximal exercise bout increases the number of circulating CD34+ /KDR+ endothelial progenitor cells in healthy subjects. Relation with lipid profile. *J Appl Physiol* 104: 1006–1013, 2008.
116. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher A, and Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circulation* 103: r21–r26, 2001.
117. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, and Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 89: e1–e7, 2001.
118. Walther C, Gaede L, Adams V, Gelbrich G, Leichtle A, Erbs S, Sonnabend M, Fikenzer K, Korner A, Kiess W, Bruegel M, Thiery J, and Schuler G. Effect of increased exercise in school children on physical fitness and endothelial progenitor cells: a prospective randomized trial. *Circulation* 120: 2251–2259, 2009.
119. Wang CH, Ciliberti N, Li SH, Szmítko PE, Weisel RD, Fedak PWM, Al-Omran M, Cherng WJ, Li RK, Stanford WL, and Verma S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. *Circulation* 109: 1392–1400, 2004.

120. Wang J, Wolin MS, and Hintze T. Chronic exercise enhances endothelium-mediated dilation of epicardial coronary arteries in conscious dogs. *Circ Res* 73: 829–838, 1993.
121. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, and Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med* 353: 999–1007, 2005.
122. Yang Z, Wang JM, Luo CF, Tang AL, and Tao J. Acute exercise-induced nitric oxide production contributes to upregulation of circulating endothelial progenitor cells in healthy subjects. *J Hum Hypertens* 21: 452–460, 2007.
123. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, and Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. *Blood* 109: 1801–1809, 2007.
124. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, and Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. *Circulation* 112: 1618–1627, 2005.
125. Zhang QJ, McMillin SL, Tanner JM, Palionyte M, Abel ED, and Symons JD. Endothelial nitric oxide synthase phosphorylation in treadmill-running mice: role of vascular signalling kinases. *J Physiol* 587: 3911–3920, 2009.

Address correspondence to:

Dr. Volker Adams

Department of Internal Medicine/Cardiology

University Leipzig—Heart Center

Strümpellstr. 39

04289 Leipzig

Germany

E-mail: adav@medizin.uni-leipzig.de

Date of first submission to ARS Central, October 27, 2010; date of acceptance, November 21, 2010.

Abbreviations Used

Ac-LDL = acetylated low-density lipoprotein
 BM = bone marrow
 BOEC = blood outgrowth endothelial cell
 CAC = circulating angiogenic cell
 CAD = coronary artery disease
 CFP = circulating endothelial precursor
 CFU-EC = colony forming unit endothelial cells
 CHF = congestive heart failure
 CV = cardiovascular
 ECFC = endothelial colony-forming cells
 ecSOD = extracellular superoxide dismutase
 eNOS = endothelial nitric oxide synthase
 EPC = endothelial progenitor cell
 EPO = erythropoietin
 FGF = fibroblast growth factor
 GM-CSF = granulocyte-macrophage colony-stimulating factor
 GPX = glutathione peroxidase
 H₂O₂ = hydrogen peroxide
 HIF-1 α = hypoxia-inducible factor 1 α
 HPP = high proliferative potential
 LPP = low proliferative potential
 MMP = matrix metalloproteinase
 MNC = mononuclear cell
 MnSOD = manganese superoxide dismutase
 NADPH oxidase = nicotinamide adenine dinucleotide phosphate-oxidase
 NF- κ B = nuclear factor-kappaB
 NO = nitric oxide
 PAOD = peripheral artery occlusion disease
 PI3K = phosphatidylinositol 3-kinase
 ROS = reactive oxygen species
 SDF-1 = stromal cell-derived factor-1
 sKitL = soluble Kit-ligand
 VEGF = vascular endothelial growth factor

This article has been cited by:

1. Juan Marcelo Fernández, Daniel Rosado#Álvarez, Marzo Edir Da Silva Grigoletto, Oriol Alberto Rangel#Zúñiga, Leslie Lorena Landaeta#Díaz, Javier Caballero#Villarraso, José López#Miranda, Francisco Pérez#Jiménez, Francisco Fuentes#Jiménez. 2012. Moderate-to-high-intensity training and a hypocaloric Mediterranean diet enhance endothelial progenitor cells and fitness in subjects with the metabolic syndrome. *Clinical Science* **123**:6, 361-373. [[CrossRef](#)]